Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B
GSK Emerges As A Contender As Others Struggle
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.
You may also be interested in...
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.